Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes care"
DOI: 10.2337/dc21-1288
Abstract: OBJECTIVE High plasma triglyceride (TG) is an independent risk factor for cardiovascular disease. Fibrates lower TG levels through peroxisome proliferator-activated receptor α (PPARα) agonism. Currently available fibrates, however, have relatively low selectivity for PPARα. The… read more here.
Keywords: ppar; pemafibrate selective; ppar modulator; 877 pemafibrate ... See more keywords
A New Selective PPARγ Modulator Inhibits Triglycerides Accumulation during Murine Adipocytes’ and Human Adipose-Derived Mesenchymal Stem Cells Differentiation
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms21124415
Abstract: Understanding the molecular basis of adipogenesis is vital to identify new therapeutic targets to improve anti-obesity drugs. The adipogenic process could be a new target in the management of this disease. Our aim was to… read more here.
Keywords: human adipose; adipocytes human; murine; ppar modulator ... See more keywords
Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis
Sign Up to like & getrecommendations! Published in 2023 at "Metabolites"
DOI: 10.3390/metabo13050626
Abstract: Statins, the intestinal cholesterol transporter inhibitor (ezetimibe), and PCSK9 inhibitors can reduce serum LDL-C levels, leading to a significant reduction in cardiovascular events. However, these events cannot be fully prevented even when maintaining very low… read more here.
Keywords: ppar modulator; nonalcoholic fatty; pemafibrate; fatty liver ... See more keywords